Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

Roche (RHHBY) announced that the European Commission has granted marketing authorization to subcutaneous ("SC”) (under the skin) injection of the cancer immunotherapy drug Tecentriq (atezolizumab).The authorization applies to all approved indications of intravenous (“IV”) formulation of Tecentriq and makes it the European Union’s first programmed death ligand-1 (PD-L1) cancer immunotherapy for subcutaneous injection.Tecentriq IV is approved for the treatment of a certain type of early-stage (adjuvant) non-s ...